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Abstract
The spread of carbapenem-non-susceptible Klebsiella pneumoniae strains bearing different
resistance determinants is a rising problem worldwide. Especially infections with KPC
(Klebsiella pneumoniae carbapenemase) - producers are associated with high mortality
rates due to limited treatment options. Recent clinical studies of KPC-blood stream infec-
tions revealed that colistin-based combination therapy with a carbapenem and/or tigecy-
cline was associated with significantly decreased mortality rates when compared to colistin
monotherapy. However, it remains unclear if these observations can be transferred to K.
pneumoniae harboring other mechanisms of carbapenem resistance. A three-dimensional
synergy analysis was performed to evaluate the benefits of a triple combination with mero-
penem, tigecycline and colistin against 20 K. pneumoniae isolates harboring different β-lac-
tamases. To examine the mechanism behind the clinically observed synergistic effect,
efflux properties and outer membrane porin (Omp) genes (ompK35 and ompK36) were
also analyzed. Synergism was found for colistin-based double combinations for strains ex-
hibiting high minimal inhibition concentrations against all of the three antibiotics. Adding a
third antibiotic did not result in further increased synergistic effect in these strains. Antago-
nism did not occur. These results support the idea that colistin-based double combinations
might be sufficient and the most effective combination partner for colistin should be chosen
according to its MIC.
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Introduction
The global spread of extended-spectrum β-lactamase (ESBL) producing enterobacteria has re-
sulted in a worldwide increase in carbapenem consumption. This selective pressure has fos-
tered the emergence and spread of carbapenem hydrolyzing β-lactamase variants, like KPC,
OXA-48, VIM or NDM in Gram-negative bacteria [1]. Of these, the class KPC-carbapenemase
is most frequently associated with K. pneumoniae but also metallo-β-lactamases (MBLs) and
the carbapenemase OXA-48 are regionally widespread in this species. The first K. pneumoniae
infection associated with KPC was reported in 2001 in the USA [2]. Presently, KPC-producing
K. pneumoniae strains have spread across the north-eastern USA and southern European
countries. In northern European countries KPC have been endemically reported [3]. In con-
trast, the proportion of KPC in K. pneumoniae blood stream infections in southern European
countries was recently reported with up to 49.8% (Greece) [3].
KPC infections are related with high mortality rates of> 50% [4, 5] and treatment options
are often limited by further resistances to other classes of antibiotics, e.g. fluoroquinolones [6].
Besides KPC, other β-lactamases are frequently co-produced, e.g. TEM, SHV, CTX-M and
OXA variants, resulting in a high resistance to all β-lactams. Moreover, usage of carbapenems
triggers the occurrence of K. pneumoniaemutants that lose the major outer membrane porins
OmpK35 and/or OmpK36. Loss of these porins is known to contribute to carbapenem resis-
tance e.g. by increasing the minimal inhibitory concentration (MIC) of carbapenems in ESBL
producers [7]. First outbreaks caused by carbapenem-non-susceptible K. pneumoniae with
ESBLs (CTX-M-15 or SHV-12) and defective OmpK-porins have been recently reported from
Italy [8], Portugal [9], and Greece [10].
In retrospective studies, reduced mortality rates were found among patients with various in-
fections caused by KPC-producing K. pneumoniae under combination antimicrobial therapy
when compared with patients receiving a monotherapy [11, 12]. In this context, the most fre-
quent combinations were colistin or tigecycline plus a carbapenem. In one of these studies, the
triple-drug combination, including tigecycline, colistin and meropenem, was associated with
the highest survival rate [12]. The synergism of the colistin / tigecycline combination against
various resistant Enterobacteriacae was demonstrated in vitro by checkerboard and time-killing
studies and in vivo in a simple animal model (Galleria mellonella) [13]. However, the mecha-
nism of this synergistic effect is still elusive.
Based on these previous studies, we performed in vitro experiments using a 3-dimensional
checkerboard assay of colistin, tigecycline and meropenem primarily against clinical multi-
drug-resistant K. pneumoniae isolates harboring different β-lactamase types. Furthermore, we
analyzed the efflux and the porin genes of these isolates to obtain an insight into the mecha-
nisms of synergistic effects of this antimicrobial combination.
Material and Methods
Microorganisms and media
All clinical K. pneumoniae isolates (n = 20) used in this study were provided by the Robert
Koch Institute (Wernigerode, Germany), the National Reference Laboratory for Multidrug-re-
sistant Gram-negative Bacteria (Bochum, Germany) and the Institute of Medical Microbiology
(Jena, Germany). All strains exhibited different antimicrobial susceptibility patterns and con-
tained different β-lactamases and therefore are referred as non-clonal (Table 1). In order to es-
tablish the K. pneumoniae efflux phenotype, we also included 20 carbapenem-susceptible K.
pneumoniae with an ESBL-phenotype that were retrieved from a current screening program in
our institution (S1 Table). The MIC of each antibiotic was determined by broth microdilution
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technique in accordance to European Antimicrobial Susceptibility Testing Committee
(EUCAST) standards [ISO 20776–1:2006]. Colistin (Sigma Aldrich, Germany), tigecycline
(Sigma Aldrich, Germany) and meropenem (Hexal, Germany) were prepared as stock solu-
tions of 100 mg/mL and stored in aliquots at—20°C. Test solutions were prepared immediately
before usage. Cation-adjusted Mueller-Hinton (MH) broth (Carl Roth GmbH, Germany) or
MH agar were prepared according to the manufacturer’s instructions.
Three dimensional checkerboard assays
Bacterial cells were cultivated overnight at 35°C at constant rotation (200 rpm) in MH broth.
The overnight cultures were adjusted to 0.5 McFarland (equivalent to 108 CFU/mL) and dilut-
ed 1:100 with broth to obtain a 106 CFU/mL suspension. For the checkerboard assay, the broth
microdilution method was modified by including some additional antibiotic concentrations.
Into each well of a standard microwell plate 100 μL of the 106 CFU/mL bacterial suspensions
were transferred and mixed with an equal volume of antimicrobial solution. For each
strain and antibiotic the selected concentration ranges depended on previously
determined MICs. In total, 11 dilution steps of meropenem, 7 dilution steps of tigecycline and
6 dilution steps of colistin were analyzed (Fig 1). The microwell plates were incubated at 35°C
for 16–20 h and interpreted according to EUCAST breakpoints for Enterobacteriaceae. Each
test was performed at least in duplicate and included a growth control without addition of
any antibiotic.
The fractional inhibitory concentration index (FICI) for each double (Eq 1) or triple (Eq 2)















The FICIs were calculated using the concentrations in the first non-turbid well found in
each row and column along the turbidity / non-turbidity interface and expressed as the median
value. We used the median averaged FICI values instead of the lowest value to avoid over-inter-
pretation of the synergism due to methodological (one-well) errors of the double dilution
method. In this regard, we refer to the FICI interpretation proposed by [14]: FICI< 0.8 syner-
gy, 0.8< FICI< 4 additive effects or indifference, and FICI 4 antagonism. We recorded the
lowest FICI values of the combinations (Table 1, indicated in brackets) as some authors prefer
those, but we did not discuss these vales.
Combined disk diffusion test
The disk diffusion test was preformed according to EUCAST rules for antimicrobial suscepti-
bility testing. Bacterial suspensions of 0.5 McFarland were spread over the surface of the MH
agar plates (diameter 90 mm) using a sterile swab. On sterile cellulose discs (diameter 6 mm)
10 μL of each antibiotic solution were applied to obtain 40 μg meropenem, 20 μg colistin and
15 μg tigecycline per disc. The three disks where placed at different distances to examine single
and combination effects of the antibiotics on bacterial growth. Synergism was defined as ex-
tended edge of the inhibition zone of one antibiotic towards the disc of another antibiotic.
Synergy Testing
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Analysis of porin genes
The porin genes ompK35 and ompK36 were amplified and sequenced by using primers de-
scribed previously [15]. The obtained nucleotide sequences were compared with wild-type
ompK sequences of K. pneumoniae strain JM45 (accession number CP006656) available at the
NCBI database.
Efflux assay
A novel fluorescent arylidenehydantoin piperazine dye BM-27 was used for the assay (Bohnert
JA and Handzlik, J, manuscript in preparation), which is virtually non-fluorescent in aqueous
solution but fluoresces strongly upon binding to periplasmic phospholipids. BM-27 was
Fig 1. Schematic set-up of three-dimensional checkerboard technique.Concentrations of each drug
increase towards the arrow. The FICI values were determined for each combination: meropenem /
tigecycline, meropenem / colistin, tigecycline / colistin and meropenem / tigecycline / colistin.
doi:10.1371/journal.pone.0126479.g001
Synergy Testing
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developed in a set of N3- aminealkyl arylidenehydantoin derivatives [16] that are substrates
and inhibitors of the MDR efflux pump AcrAB-TolC [17].
20 mL of the overnight cultures were centrifuged and washed twice with potassium phos-
phate buffer (PPB) containing 12.5 mM K2HPO4, 7.8 mM KH2PO4 and 1 mMMgCl2 (pH 7).
The bacterial pellets were resuspended in PPB and adjusted to an optical density of 0.5 at 600
nm. The efflux assay was performed in flat, transparent 96-well plates (Greiner, Germany)
using Infinite M200Pro spectrometer (Tecan, Switzerland). In each well 200 μL bacterial sus-
pensions and 15 μM carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (Sigma Aldrich)
were mixed and incubated for 8 min at room temperature to disrupt the residual proton gradi-
ent of the cells. Bacterial cells were labeled with 50 μM of BM-27. Fluorescence intensity
was determined at 400 nm excitation and 457 nm emission. The treatment time varied depend-
ing on the labeling of the respective strains and was completed by reaching a constant fluores-
cence signal (steady-state). By adding glucose to a final concentration of 50 mM the efflux of
the BM-27 dye was initiated and the time-resolved decrease of the fluorescence signal was mea-
sured. The obtained curves could be best fitted by applying the general fit for one-phase expo-
nential decay (Eq 3) using GraphPad Prism 6.00 (GraphPad Software, La Jolla California
USA):
y ¼ ðFmax  FminÞ  eKX þ Fmin ð3Þ
Where y is the measured fluorescence signal, x represents the time ordinate, Fmax represents
the fluorescence signal at x = 0; Fmin represents the fluorescence signal at infinite time. The ef-
flux half-time (EHT) corresponds to the term 0.6932/K and was used as ratio to compare the
efflux properties. The labeling efficiency ΔF was given by fluorescence difference of Fmax to
Fmin.
Statistical analyses
Differences between two groups (e.g. ompKmutation absent or present) for several semi-quan-
titative FICIs (FICIMER/TGC, FICIMER/CST, FICITGC/CST and FICIMER/TGC/CST) were investigated
by exact non-parametric Wilcoxon-Mann-Whitney tests and quantified by median differences
and 95% confidence intervals (CIs). Similarly we determined non-parametric Spearman’s rank
correlation coefficients ρ (and 95% CIs) for semi-quantitative variables MICs and efflux with
FICIs. We applied a two-sided significance level of 5% and report nominal two-sided p-values.
Wilcoxon-Mann-Whitney tests were conducted using the statistical language R version 3.0.3
and the Spearman correlations were calculated using SAS version 9.3.
Results
Phenotypic and genotypic characterization of the resistances
All 20 analyzed clinical K. pneumoniae isolates harbored at least two various β-lactamases, in-
cluding narrow-spectrum-β-lactamases (TEM-1, SHV-1, SHV-11 and/or OXA-11), ESBLs
(CTX-M-15, OXA-1 and/or VEB-1) and carbapenemases (OXA-48, VIM-1 and/or KPC), re-
sulting in different resistance profiles (according to EUCAST breakpoints) (Table 1). In three
isolates additional non-functional OXA-9 genes were determined due to a nonsense mutation.
In total, 16 strains (80%) were meropenem-resistant (MICMEM > 8 mg/L). Within these, 5
showed susceptible or intermediate MICs for tigecycline (MICTGC  1 mg/L) and colistin
(MICCST  2 mg/L), 7 were resistant to colistin (MICCST > 2 mg/L) and 4 were resistant to all
three drugs. Four strains showed intermediate MICs for meropenem (MICMEM > 2–8 mg/L).
Within these, one isolate was resistant and three were intermediate to tigecycline and colistin.
Synergy Testing
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Analysis of porin genes ompk35 and ompk36
Sequence analyses revealed that all strains exhibited mutations in the ompK genes. Three
strains lost OmpK35 and three other strains lost OmpK36 due to nonsense mutations in the re-
spective genes. One strain exhibited only a modified OmpK36. One strain lost both porins
whereas 10 strains lost the OmpK35 but harbored modified OmpK36 (Fig 2).
The altered ompK35 genes contained frame shift mutation due to one bp insertions (NRZ
04322, RKI 551/13, RKI 85/14, RKI 318/11, RKI 105/10, RKI 412/11, NRZ 05989) or one bp
deletions (RKI 84/14, NRZ 01839, NRZ 02915, RKI 346/12, RKI 83/14, NRZ 03656), or one
amino acid substitutions (RKI 536/13, NRZ 01732a, NRZ 06142) resulting in intergenic stop
codons (data not shown) and consequently in early termination of the peptides. Alterations of
gene ompK36 were more variable. Two strains (RKI 84/14 and RKI 83/14) contained insertion
sequences (IS5) within ompK36 disrupting the open reading frame. Substitutions leading to
stop codon TAG and early termination of OmpK36 were found at amino acid position 146 in
NRZ 00246, at position 245 in RKI 178/11, and at position 316 in RKI 105/10. Two strains
(RKI 536/13 and NRZ 06142) revealed deletions at amino acid position 228–229 leading to a
frame shift with the consequence of prolonged peptide of unknown effect. Seven strains
showed an insertion of 2 amino acids (glycine and aspartic acid) at positions 136 and 137 that
are located within the highly conserved domain of loop structure L3 [18]. This mutation has
been described to be associated with increased carbapenemMICs [19].
Further sequence modifications within the ompK36 gene were found in some isolates
(S2 Table) but the consequences for the function of the proteins were not studied in this work.
Amino acid substitutions or in-frame insertions or deletions may lead to altered functions but
are unlikely to result in total loss of the porin.
Characterization of the efflux properties
The novel fluorescent dye BM-27 was used to measure the efflux properties of the strains. Con-
trary to other known membrane probes like Nile red [20], BM-27 is readily water soluble so no
organic solvents with potentially antibacterial effects are needed.
Fig 2. Sequence alignment of ompK36 genes. The sequence of ompK36 of K. pneumoniae strain JM45 (accession number CP006656) was used as
reference. The boxes marked the most relevant changes within the ompk36 sequences. Alterations are described above the boxes and the positions of the
corresponding amino acid residues are indicated below the boxes.
doi:10.1371/journal.pone.0126479.g002
Synergy Testing
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Since no comparable data exist for K. pneumoniae, we first analyzed and interpreted the dis-
tribution of the maximal labeling efficiency by the fluorescent dye as well as the distribution of
the efflux half-time (EHT) including ESBL K. pneumoniae isolates with meropenem susceptible
phenotype. In general, it is more difficult to label K. pneumoniae strains with any dye com-
pared to e.g. Escherichia coli due to the stronger outer membrane charge [21]. In the present
study only one meropenem resistant strain (RKI 412/11) could not be suitably labeled for the
efflux assay and therefore we cannot make any conclusions about its efflux properties. For the
other strains labeling of> 900 fluorescence units were obtained and efflux curves were evalu-
able (S1 Fig). The influx and efflux distributions did not differed between meropenem resistant
and susceptible isolates (p values 0.247 and 0.879, respectively). The influx properties seemed
to be independent of the OmpK-porins since no correlation could be observed between ΔF and
the respective porin mutation indicating that BM-27 might use other channels or mechanism
to penetrate the cell wall.
EHT values were considered to interpret the efflux data. Most of the strains exhibited EHT
values of 40–50 seconds (30%) or 50–60 seconds (35%), 15% showed EHT values of 60–70 sec-
onds, whereas 5% showed EHT values of 70–80 seconds and 15% even higher values of 80–90
seconds (S1 Fig). Compared to other studies on E. coli efflux, 50–70 seconds correspond to
moderate efflux whereas lower values indicate an enhanced efflux and higher values impaired
efflux [20].
Synergism testing
Except two isolates (RKI 536/13 harboring KPC-2 and NRZ 00246 harbouring OXA-48) that
exhibit FICIMEM/TGC of 0.74 and 0.75, no synergism was found for meropenem-tigecycline
combination in all other strains (Table 1).
Synergism of all three colistin-based combinations (MEM / CST, TGC / CST and MEM /
TGC / CST) was found in 5 isolates (Fig 3A–3C). For one additional isolate, only MEM / CST
and for another one TGC / CST and MEM / TGC / CST synergies were found. A clearly visible
reduction of the FICIMEM/TGC/CST compared to FICITGC/CST could not be observed for the iso-
lates with synergism (Table 1) indicating that the addition of meropenem to the tigecycline /
colistin combination or tigecycline to the meropenem / colistin combination did not increase
the antimicrobial efficacy. No significant correlation of the MICMEM to the FICIMEM/CST or
FICIMEM/TGC/CST could be determined. However, all isolates with FICIMEM/CST < 0.8 exhibited
MICMEM of 8 mg/L and carried various β-lactamase variants (KPC, OXA-48 or CTX-M-15)
indicating that there is also no causal relationship between the β-lactamase type and synergism
with colistin. The MICs for colistin showed some weak correlation with FICITGC/CST (ρ =
-0.52, P = 0.017) and FICIMEM/TGC/CST (ρ = -0.61, P = 0.003). Isolates with synergism generally
showed increased MICCST values (MICCST > 8 mg/L). Similar correlations were found between
increased resistance to tigecycline (MICTGC) and the FICIMEM/TGC (ρ = -0.70, P<0.001),
FICITGC/CST (ρ = -0.70, P< 0.001) and FICIMEM/TGC/CST (ρ = -0.73, P< 0.001). All isolates
with synergism exhibited MICTGC  2 mg/L. A correlation between the efflux properties and
the FICI values could not be shown. For detailed results see S3 Table.
The MIC for at least one antibiotic could be strongly reduced in combination for highly re-
sistant strains (Fig 4, S2 and S3 Figs): For the combination of colistin and tigecycline both
MICs could be decreased below the EUCAST breakpoints.
Within the six isolates exhibiting synergistic effects (Table 1, FICIs in bold letters), four
were found with loss of OmpK36 porin due to two non-senses mutations, one IS5-insertion
and one frame shift mutation in the ompK36 gene sequence, respectively. The two remaining
isolates showed identical alterations of OmpK36 due to the insertion of glycine and aspartic
Synergy Testing
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acid in the L3 structure. Within these two isolates carried only narrow-spectrum and ESBL β-
lactamases but non carbapenemase.
Disk diffusion test
Disk diffusion tests were performed to supplement the results of the checkerboard assay. We
selected 7 isolates exhibiting synergistic effects and 2 isolates that showed no synergism.
Fig 3. Exemplary isoboles of the double combinations of the antibiotics. A-C: Isoboles of strain NRZ 00246 (OXA-48 producer) exhibiting synergistic
effects. D-F: Isoboles of strain RKI 318/11 (KPC producer) yielding no synergism. FIC = fractional inhibitory concentration.
doi:10.1371/journal.pone.0126479.g003
Synergy Testing
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Fig 4. Exemplary plots of the checkerboard assays for the double combinations of the antibiotics. A-C: Strain NRZ 00246 (OXA-48 producer)
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Compared to the checkerboard test similar synergistic pattern were found for four strains
(RKI 563/13, RKI 178/11, NRZ 04322 and RKI 551/13). For the strains NRZ 00246, RKI 84/14
and RKI 85/14 no clear synergism between colistin and the other antibiotics was visible, but
synergistic effects of meropenem and tigecycline were found for these strains (Fig 5). Syner-
gism of meropenem and tigecycline was also visible for two exemplary strains revealing no syn-
ergism in the checkerboard assay (NRZ 06142 and RKI 318/11). In this test, growth of mutants
inside the inhibition zone of the respective antibiotic (in case of RKI 563/13: meropenem and
Fig 5. Inhibition zones of the antibiotics in disc diffusion test of selected strains.
doi:10.1371/journal.pone.0126479.g005
Synergy Testing
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colistin; RKI 85/14 and NRZ 06142: meropenem; and NRZ 04322 and RKI 84/14: colistin) was
suppressed by the activity of the synergistic agonist tigecycline.
Discussion
The number of K. pneumoniae isolates with reduced susceptibility to carbapenems increases
annually and often this phenotype is carbapenemase independent. In the present study, to date
rarely addressed porin defects were observed in all analyzed K. pneumoniae isolates (Table 1).
Carbapenemase producers (KPC, OXA-48 or VIM-1) were consistently highly resistant to
meropenem but also the MICMEM of five isolates harboring only ESBL variant CTX-M-15 or
additionally the narrow-spectrum β-lactamase OXA-1 varied from 4 mg/L to 32 mg/L. The in-
creased MICs for meropenem are most probably caused by the loss of the porins OmpK35
and/or OmpK36 as described previously [8, 22, 23]. Based on our results the proportional con-
tribution of both OmpK-porins to the MICMEM remains unclear since no explicit pattern, due
to the isolated loss of OmpK35 or OmpK36, could be evaluated. However, other studies dem-
onstrated that both porins contribute to the carbapenem resistance in K. pneumoniae [24].
While loss of Omp35 alone was shown to have weak effects, OmpK36 is stronger associated
with increased cephalosporine and carbapenemMICs of ESBL and AmpC producers and loss
of both porins was shown to strongly elevate the resistance to most cephalosporines and carba-
penems [22, 23]. Interestingly, isolate RKI 84/14 exhibit an exceptional high MICMEM of 32
mg/L. Since this isolate showed similar omp-mutation and similar β-lactamase variants com-
pared to isolate RKI 83/14, the reduced meropenem susceptibility seems to be triggered by fur-
ther unknown factors. In this context, loss of the porins LamB [25] or PhoE [26] that have
been shown to contribute to carbapenem resistance or increased expression of the CTX-M
gene might be involved but were not investigated in this work. The efflux properties of all study
isolates could not been directly correlated to the MICMEM or MICCST or MICTGC.
Using the checkerboard assay synergism of double and triple antibiotic combinations was
identified in 30% of the K. pneumoniae isolates with phenotypic carbapenem resistance but
was not significantly increased for the triple combination. Similar to a recently published work,
no significant correlation between the synergistic effect of colistin / meropenem and loss or
modifications of OmpK36 porin could be identified [27].
Retrospective clinical data indicated improved outcome for KPC K. pneumoniae infections
for treatments including at least one drug with in vitro confirmed activity [28]. In the present
study, synergistic effects were only observed for isolates with high MICMEM (> 8 mg/L) that si-
multaneously exhibited high MICCST (> 8 mg/L) and / or MICTGC (> 2 mg/L) and thus were
classified as resistant to all three antibiotics. It has to be mentioned that the predictive value of
in vitro antimicrobial susceptibility testing (AST) is often limited by various methodological
and individual factors (focus of infection, co-morbidities or co-infections, antibiotic blood and
tissue levels) [29]. Nevertheless, in vitro synergy testing might be helpful to elucidate the best-
performing therapeutic partners. In this study the synergism was dominantly observed in colis-
tin-based combinations, which may be explained as follows: The β-lactam antibiotics act within
the periplasmatic space and primary pass though the outer membrane via the major porins
OmpK35 and OmpK36 [30]. Tigecycline acts in the cytoplasm by inhibiting the 30S subunit of
the ribosome [31] and has to cross both membranes. Colistin is a amphiphilic polymyxin and
is known to interact with lipoid compounds and to induce instability and pore-formation in
bacterial membranes [32], and thus it might promote the membrane translocation of merope-
nem and tigecycline. To overcome the increased resistance against periplasmatic or intracellu-
lar active antibiotics, higher concentrations of these antibiotics have to be achieved in the
respective cell compartment. The colistin enhanced membrane translocation might be only
Synergy Testing
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realized in colistin resistant strains that can accumulate higher amounts of colistin without
timely killing of the bacteria. This supports the idea that there is a relation between the perme-
ability of the cell wall and membrane and the restored antimicrobial efficacy of meropenem
and tigecycline even against resistant isolates by disregarding of the resistance mechanisms due
to saturated antibiotic concentrations. A similar mechanism was proposed for the colistin-dori-
penem-ertapenem combination [27].
In the clinical context, synergism is only of value if the MICs of at least one combination
partner are decreased below the respective breakpoint. Therefore we alternatively plotted MICs
of the double antibiotic combinations (Fig 4) and compared the effective combined concentra-
tions to EUCAST breakpoints. In our opinion these plots better illustrate the benefits of the re-
spective combinations against individual strains. This allowed conclusions of the impact of
each antibiotic to achieve an effective combination therapy. For example: Strain NRZ 00246
was meropenem, tigecycline and colistin resistant, and for all double combinations the FICIs
indicated synergism. The simple plots clearly showed that meropenem combined with tigecy-
cline (Fig 4A) or colistin (Fig 4B) reduced the required concentration of both antibiotics, but
combined low concentrations of tigecycline and colistin were within the therapeutic window
(and even within the breakpoints) of both antibiotics. Thus this combination seemed to be
more effective (Fig 4C).
We could not determine synergistic effects in strains with a low MIC for one of the three
tested antibiotics. It cannot be excluded that some synergism may become unnoticed due to
the microdilution technique and the chosen concentration, but we favor the hypothesis that in
susceptible strains one effective antibiotic is sufficient for growth inhibition in vitro. The plots
in Fig 4D–4F demonstrate the distribution of the combined MICs in a susceptible strain, where
no increase in FICI values was observed. Not surprisingly, all MICs are located below the
breakpoints for the respective antibiotics.
Studies investigating colistin pharmacokinetic (PK) revealed that much higher dosages than
the traditionally used 3 x 1 million units are required to achieve a serum concentration above 2
mg/L [33]. However, since colistin can cause serious side effects, increasing dosages is limited
by toxicity [34]. In this study, we could show that even in colistin resistant strains a low colistin
dosage (below 2 mg/L) is able to reduce the MIC or even restore the susceptibility against mer-
openem and tigecycline. The studied isolates were all defective in one or two major porins.
These mutations are associated with increased carbapenem resistance in K. pneumoniae [7].
Thus most likely the synergistic mechanism is driven by colistin-induced facilitated transloca-
tion of meropenem and tigecycline though the outer and inner membranes. In line with our re-
sults, a recent retrospective analysis of carbapenemase-producing K. pneumoniae bloodstream
infections did not find an advantage of the carbapenem-tigecycline combination but carbape-
nem-colistin and colistin-tigecycline combinations [35]. However, improved outcome of pa-
tients infected by K. pneumoniae under carbapenem-tigecycline combination therapy was
observed in other retrospective studies [36, 37] suggesting that in vitro data might poorly reflect
the in vivo efficiency. A combination therapy, even if not clearly synergistic in in vitro test,
might be more effective than a monotherapy and prevent the emergence of resistant mutants
as indicated by the disc diffusion assay in this study.
Conclusion
Combination therapy offers a perspective to threat even highly resistant strains. Our in vitro re-
sults suggest that the best appropriate combination therapy to treat carbapenem resistant K.
pneumoniaemight be colistin / tigecycline. In highly resistant strains relevant synergism was
detected resulting in a MIC that would have been clinically achievable by conventional dosing.
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What do our observations mean for current clinical practice? Colistin seems to be the most
effective part of these combinations. Antagonism even in triple combinations is unlikely. Even
low colistin concentrations (< 2 mg/L) were able to restore meropenem and tigecycline suscep-
tibility. Therefore, sufficient dosing of colistin may be more important than adding a third
drug to a double combination. Adding a third antibiotic to a colistin based double combination
might be only useful in vivo if the MIC of colistin is elevated but data confirming these hypoth-
esis are elusive.
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